Engineering
Chemicals
Consumer Products

ChromaDex

$3.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ChromaDex and other stocks, options, ETFs, and crypto commission-free!

About

ChromaDex Corporation Common Stock, also called ChromaDex, is a nutraceutical company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. Read More The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Irvine, CA.

Employees
100
Headquarters
Los Angeles, California
Founded
1999
Market Cap
217.60M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
255.15K
High Today
$4.02
Low Today
$3.89
Open Price
$3.92
Volume
67.09K
52 Week High
$5.00
52 Week Low
$2.79

Collections

Engineering
Chemicals
Consumer Products
Health And Wellness
Retail
Health
2016 IPO
US

News

Yahoo FinanceMar 13

Edited Transcript of CDXC earnings conference call or presentation 7-Mar-19 9:30pm GMT

Q4 2018 Chromadex Corp Earnings Call Irvine Mar 13, 2019 (Thomson StreetEvents) -- Edited Transcript of Chromadex Corp earnings conference call or presentation Thursday, March 7, 2019 at 9:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Brianna Gerber ChromaDex Corporation - Sr. Director of FP&A and IR * Frank Louis Jaksch ...

36
Yahoo FinanceMar 11

ChromaDex to Present at the 31st Annual ROTH Conference

LOS ANGELES, March 11, 2019 (GLOBE NEWSWIRE) -- ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 31st annual ROTH Capital Partners Conference at the Ritz-Carlton in Dana Point, CA. The ChromaDex management team is scheduled to present on Monday, March 18, at 3:30 p.m. Pacific Time. ChromaDex management will also attend one-on-one meetings with institutional investors thro...

11
MarketBeatMar 8

Stock Price, News, & Analysis for Chromadex

ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improv...

1

Earnings

-$0.17
-$0.10
-$0.03
$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.